SAFFRON Data Reveal New Global SOC in EGFR+ NSCLC With MET Overexpression and/or Amplification After Osimertinib
Osimertinib plus savolitinib improved progression-free and overall survival in EGFR-mutated NSCLC patients with MET overexpression/amplification after osimertinib progression, per SAFFRON trial. Median PFS: 7.6 vs 5.4 months (HR 0.55, P < .001). Median OS: 17.8 vs 12.9 months (HR 0.68, P = .010). FDA application submitted in September 2026.
How this was made
The 30-second read
Why it matters
The trial met its primary and key secondary endpoints, prompting an FDA new drug application and likely influencing treatment guidelines.
Market read
First disclosure of pivotal data and regulatory filing provides fresh catalyst for AstraZeneca and may affect oncology biotech valuations.
What to watch
Potential competition from other MET inhibitors and the need for reimbursement approvals could limit upside.
Background
The SAFFRON trial evaluated osimertinib plus savolitinib versus chemotherapy in EGFR‑mutated NSCLC patients with MET alterations after progression on osimertinib.
Ticker impact
Phase 3 SAFFRON trial results for osimertinib plus savolitinib were first disclosed, showing significant PFS and OS benefits and prompting an FDA NDA submission.
likely upward pressure as investors price in the new indication and potential market expansion.
First-time disclosure of pivotal trial outcomes and regulatory filing provides fresh, material information that can move the stock.
Market effects
Strengthens the broader oncology/targeted therapy sector, potentially boosting peer biotech stocks.
May benefit European biotech markets where AstraZeneca has a strong presence.
Adds a new treatment option for EGFR‑mutated NSCLC globally, influencing worldwide oncology pipelines.
Counterpoint
If the FDA raises concerns about safety or the market has already priced in the data, the stock could face disappointment.
Key entities
- CompanyAstraZeneca
Pharmaceutical company developing the osimertinib/savolitinib combination.
- DrugSavolitinib
MET inhibitor combined with osimertinib in the trial.
